Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Allergy. 2023 Jan;78(1):214-224. doi: 10.1111/all.15508. Epub 2022 Sep 15.
The diagnosis of allergic reactions to penicillins (AR-PEN) is very complex as there is a loss of sensitization over time, which leads to negative skin tests (STs) and specific IgE in serum, and even to tolerance to the drug involved. However, STs may become positive after subsequent exposure to the culprit drug (resensitization), with the risk of inducing potentially severe reactions. The exact rate of resensitization to penicillins is unknown, ranging from 0% to 27.9% in published studies.
To analyze the rate of resensitization in patients with suggestive AR-PEN by repeating STs (retest) after an initial evaluation (IE).
Patients with suspected AR-PEN were prospectively evaluated between 2017 and 2020. They underwent STs, and a randomized group also underwent a drug provocation test (DPT) with the culprit. Only patients with negative STs and/or DPT were included. All included cases were retested by STs at 2-8 weeks.
A total of 545 patients were included: 296 reporting immediate reactions (IRs) and 249 non-immediate reactions (NIRs). Eighty (14.7%) cases had positive results in retest (RT+): 63 (21.3%) IRs and 17 (6.8%) NIRs (p < 0.0001). The rate of RT+ was higher in anaphylaxis compared with all other reactions (45.8% vs 9.1%, p < 0.0001). The risk of RT+ was higher from the fifth week after IE (OR: 4.64, CI: 2.1-11.6; p < 0.001) and increased with the patient's age (OR: 1.02; CI: 1.01-1.04; p = 0.009).
Due to the high rate of resensitization, retest should be included in the diagnostic algorithm of IRs to penicillins after an initial negative study, especially in anaphylaxis, to avoid potentially severe reactions after subsequent prescriptions of these drugs.
青霉素过敏反应(AR-PEN)的诊断非常复杂,因为随着时间的推移会发生致敏性丧失,这会导致皮肤试验(ST)和血清特异性 IgE 呈阴性,甚至对所涉及的药物产生耐受性。然而,在随后接触罪魁祸首药物后,ST 可能会再次呈阳性(再致敏),从而有引发潜在严重反应的风险。青霉素再致敏的确切发生率尚不清楚,在已发表的研究中为 0%至 27.9%。
通过在初始评估(IE)后重复 ST(复测)来分析具有提示性 AR-PEN 的患者的再致敏率。
2017 年至 2020 年期间,前瞻性评估疑似 AR-PEN 的患者。他们接受了 ST 检查,随机分组的患者还接受了与罪魁祸首药物的药物激发试验(DPT)。仅纳入 ST 和/或 DPT 阴性的患者。所有纳入的病例均在 2-8 周后通过 ST 进行复测。
共纳入 545 例患者:296 例报告有即刻反应(IRs),249 例报告有非即刻反应(NIRs)。80 例(14.7%)在复测时结果阳性(RT+):63 例 IRs 和 17 例 NIRs(p<0.0001)。与所有其他反应相比,过敏反应的 RT+发生率更高(45.8% vs 9.1%,p<0.0001)。IE 后第五周开始 RT+的风险更高(OR:4.64,95%CI:2.1-11.6;p<0.001),且随着患者年龄的增长而增加(OR:1.02;95%CI:1.01-1.04;p=0.009)。
由于再致敏率较高,在初始阴性研究后,青霉素 IR 患者的诊断算法中应包括复测,尤其是过敏反应患者,以避免在随后开具这些药物后发生潜在严重反应。